Skip to main content

Table 2 Comparison of IC50 values for concentration-effect curves of anti-malarial drugs against Plasmodium falciparum and Plasmodium vivax generated by different programs

From: Analysis of ex vivo drug response data of Plasmodium clinical isolates: the pros and cons of different computer programs and online platforms

 

P. falciparum

 

P. vivax

Method

Geometric mean IC50 [nM] (95 % CI)

Median difference IC a50 [nM] (range)

Method

Geometric mean IC50 [nM] (95 % CI)

Median difference IC a50 [nM] (range)

Chloroquine (n = 31)

NONMEM

91.40 (74.39–108.40)

 

Chloroquine (n = 29)

NONMEM

151.9 (124.2–179.6)

 

GP

81.43 (67.67–98.00)

0.42 (−7.80 to 6.50)

GP

137.8 (115.8–163.9)

0.37 (−50.0-32.0)

HNL

81.59 (67.26–98.97)

0.42 (−5.50 to 13.0)

HNL

136.7 (114.3–163.5)

0.33 (−47.0 to 35.0)

ICE

82.59 (68.45–99.65)

1.50 (−5.00 to 11.0)

ICE

137.4 (115.7–163.2)

1.80 (−62.0 to 10.0)

IVART

83.85 (69.20–101.6)

0.93 (−12.0 to 40.0)

IVART

135.2 (113.0–161.7)

1.90 (−62.0 to 17.0)

WNL

81.40 (67.62–98.00)

0.51 (−5.40 to 5.10)

WNL

136.4 (114.7–162.1)

0.18 (−63.0 to 12.0)

Piperaquine (n = 31)

NONMEM

25.65 (20.79–30.50)

Piperaquine (n = 28)

NONMEM

26.03 (18.99–33.08)

 

GP

21.77 (17.79–26.64)

0.56 (−9.60 to 3.30)

GP

20.46 (15.51–26.99)

−0.08 (−3.80 to 2.30)

HNL

22.35 (18.30–27.30)

−0.22 (−5.10 to 13.0)

HNL

21.26 (16.21–27.89)

0.68 (−4.80 to 6.90)

ICE

22.72 (18.44–27.99)

0.44 (−3.00 to 4.90)

ICE

20.99 (15.99–27.54)

0.14 (−1.70 to 3.10)

IVART

22.10 (17.88–27.32)

−0.02 (−11.0 to 4.90)

IVART

21.34 (16.35–27.85)

0.24 (−2.20 to 3.80)

WNL

21.93 (17.92–26.85)

−0.28 (−9.20 to 3.30)

WNL

20.64 (15.68–27.18)

−0.05 (−1.80 to 1.70)

Mefloquine (n = 31)

NONMEM

13.49 (10.26–16.71)

 

Mefloquine (n = 29)

NONMEM

21.67 (15.23–28.11)

 

GP

10.99 (8.55–14.11)

0.01 (−1.30 to 2.90)

GP

16.53 (12.12–22.56)

0.27 (−0.81 to 4.40)

HNL

11.31 (8.85–14.45)

0.24 (−0.89 to 3.80)

HNL

16.61 (12.24–22.54)

0.26 (−2.30 to 3.40)

ICE

11.31 (8.84–14.46)

0.38 (−0.15 to 2.80)

ICE

16.82 (12.38–22.87)

0.56 (−0.32 to 3.20)

IVART

10.59 (8.14–13.76)

0.03 (−5.10 to 3.10)

IVART

16.61 (12.00–23.00)

0.51 (−2.50 to 5.40)

WNL

11.04 (8.59–14.17)

0.03 (−0.82 to 2.30)

WNL

16,341 (12.01–22.43)

0.12 (−1.20 to 3.00)

Amodiaquine (n = 30)

NONMEM

14.53 (12.18–16.88)

 

Amodiaquine (n = 28)

NONMEM

24.97 (20.29–29.64)

 

GP

13.40 (11.21–16.03)

−0.05 (−2.70 to 11.0)

GP

22.03 (17.4–27.80)

0.04 (−3.60 to 8.00)

HNL

13.59 (11.42–16.18)

0.46 (−2.80 to 2.60)

HNL

22.31 (17.66–28.18)

1.10 (−2.10 to 4.50)

ICE

13.24 (11.16–15.71)

0.04 (−1.10 to 0.87)

ICE

21.74 (17.34–27.25)

0.07 (−1.80 to 0.81)

IVART

13.24 (11.16–15.71)

0.04 (−1.10 to 0.87)

IVART

21.88 (17.31–27.10)

−0.03 (−1.80 to 0.81)

WNL

13.38 (11.22–15.96)

−0.04 (−1.30 to 11.0)

WNL

21.88 (17.36–27.57)

−0.02 (−2.20 to 4.30)

Artesunate (n = 31)

NONMEM

5.43 (3.23–7.63)

 

Artesunate (n = 28)

NONMEM

4.12 (2.38 to 5.85)

 

GP

3.59 (2.48–5.19)

0.01 (−0.14 to 1.10)

GP

2.47 (1.63–3.75)

0.01 (−0.64 to 0.82)

HNL

3.57 (2.52–5.07)

−0.01 (−2.60 to 11.0)

HNL

2.55 (1.69–3.85)

0.06 (−0.73 to 2.60)

ICE

3.51 (2.48–4.67)

0.05 (−0.14 to 0.99)

ICE

2.50 (1.65–3.79)

0.04 (−0.30 to 0.79)

IVART

3.54 (2.54–4.94)

0.07 (−2.90 to 0.84)

IVART

2.45 (1.61–3.72)

0.01 (−0.63 to 0.43)

WNL

3.61 (2.49–5.23)

0.01 (−0.40 to 10.0)

WNL

2.48 (1.63–3.76)

0.01 (−0.41 to 1.00)

  1. aMedian difference (range) for each method compared with NONMEM (values in italics) used as the reference method for comparison